Viewing Study NCT05363605

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:09 AM
Ignite Modification Date: 2026-01-08 @ 3:19 AM
Study NCT ID: NCT05363605
Status: TERMINATED
Last Update Posted: 2023-12-19
First Post: 2022-04-26
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Sponsor: Fusion Pharmaceuticals Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Solid Tumor View
None Head and Neck Squamous Cell Carcinoma View
None Bladder Carcinoma View
None Susceptible FGFR3 Genetic Alterations View
None FGFR3 View
None FGFR3 Overexpression View
None FGFR3 Receptor View
None FGFR3 Protein Overexpression View
None Ovarian Cancer View
None Colorectal Cancer View
None Breast Cancer View
None Liver Cancer View
None Lung Cancer View
None Gastric Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Actinium-225 View
None Targeted Alpha Therapy View
None Radiopharmaceutical View
None Radioimmunoconjugate View
None Theranostic View
None Theragnostic View
None Radioligand View
None Antineoplastic agents View
None [225Ac]-FPI-1966 View